30 closest matches · ranked by relevance
Pan Tumor
Primary: Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) - Arm A — 22.5; 38.6 Precentage of participants
Colorectal Neoplasms · Microsatellite Instability
Primary: Overall Response Rate (ORR) — 0 % of participants
Bladder Cancer · Melanoma
Primary: Confirmed Objective Response in Bladder Cancer Participants to Nivolumab Monotherapy — 23 percentage of participants with PR/CR
Non Small Cell Lung Cancer
Primary: Efficacy of Atezolizumab in Combination With Bevacizumab - PFS — 11.3 Months
Metastatic Colorectal Cancer
Primary: Objective Response Rates (RECIST 1.1) — 42.4 Percentage of participants
Neoplasm
Primary: Proportion of Patients With a Reportable Genetic Variant — 0.61 proportion of participants
Advanced Metastatic Cancer · Advanced Prostate Cancer
Primary: Clinical Benefit Rate (CBR) of Nivolumab With or Without Ipilimumab — 1; 18; 1; 1 Participants
Advanced/Metastatic Solid Malignancies
Primary: Overall Response Rate (Confirmed) — 1; 1 Participants
Recurrent Endometrial Cancer
Primary: Frequency of Objective Tumor Response as Assessed by RECIST 1.1- Overall Response Rate (ORR) — 5; 9; 7; 3 Participants — p=0.024
Non-small Cell Lung Cancer Stage I
Primary: Examine the T-cell Receptor Profile Changes Induced in the Tumor After SABR
Non-Small Cell Lung Cancer
Primary: Objective Response Rate — 40.2 Percentage of Participants
Non-small Cell Lung Carcinoma · Urothelial Carcinoma · Gastrointestinal Carcinoma, Non-colon
Primary: Overall Response Rate (ORR) in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations — 10.3; 0; 7.1; 0 percentage of participants
Melanoma · Advanced Melanoma
Primary: Number of Genes Predictive of Response at Baseline — 52 genes
Non-Small Cell Lung Cancer · Metastatic Non-small Cell Lung Cancer · Squamous Cell Carcinoma
Primary: Rate of Dose Limiting Toxicity (DLT) — 17 % participants w severe toxicity
Solid Tumor, Adult
Primary: Immune-related Objective Response Rate — 9 Participants
Cancer
Primary: Number of Participants and Type of Reported Adverse Events — 25; 22; 22; 6 Participants
Metastatic Ovarian Cancer
Primary: Number of Participants With Reported Adverse Events by Type — 3; 3; 1; 1 Participants
Non-small Cell Lung Cancer Stage III · Non-Small-Cell Lung Cancer Metastatic
Primary: Number of Patients With T790M Mutation Detected by Amplification Refractory Mutation System (ARMS) Assay — 97 participants
Prostate Cancer · Recurrent Prostate Cancer
Primary: Percentage of Participants With PSA50 Response — 2 Participants
Metastatic Triple Negative Breast Cancer
Primary: Objective Response Rate (ORR) — 0; 1; 1; 4 Participants
Locally Advanced Malignant Solid Neoplasm
Primary: Pathological Complete Response (pCR). — 67 Percentage
Advanced Lymphoma · Advanced Malignant Solid Neoplasm · Hematopoietic and Lymphoid Cell Neoplasm
Primary: Overall Response Rate (ORR) — 35.7 percentage of participants
Non-Small Cell Lung Cancer · Epigenetic Therapy
Primary: Objective Response — 4; 1; 5; 3 Participants
Advanced Lung Non-Squamous Non-Small Cell Carcinoma · Recurrent Lung Non-Squamous Non-Small Cell Carcinoma · Stage IV Lung Cancer AJCC v8
Primary: Objective Response Rate (ORR) — 2 percentage of participants
Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Determined by Investigator — 17.1…
Lung Cancer
Primary: Progression Free Survival — 16; 10.5 months
Metastatic Melanoma · Stage IIIB Cutaneous Melanoma AJCC v7 · Stage IIIC Cutaneous Melanoma AJCC v7
Primary: Overall Response Rate in Each Arm — 1; 1; 2; 1 Participants
Melanoma
Primary: Association of Baseline C11-AMT PET SUV Max Value With Objective Response — 6; 6; 1; 13 Participants — p=0.08
Anti-p53 TCR-Gene
Primary: Clinical Tumor Regression — 1 Participants
Metastatic Melanoma
Primary: Percentage of Participants With Overall Response (OR) — 38 percentage of participants